These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26446506)

  • 1. Obinutuzumab in multidrug-resistant hairy cell leukemia.
    Bohn JP; Willenbacher E; Steurer M
    Ann Hematol; 2016 Jan; 95(2):351-2. PubMed ID: 26446506
    [No Abstract]   [Full Text] [Related]  

  • 2. Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?
    Bourquin JP; Bornhauser B
    Expert Rev Hematol; 2010 Aug; 3(4):369-72. PubMed ID: 21083025
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of hairy cell leukemia variant with obinutuzumab.
    Al-Sarayfi D; Meeuwes FO; Munnink TO; Plattel W; Rosati S; Matutes E; Nijland M
    Ann Hematol; 2022 Mar; 101(3):703-704. PubMed ID: 34086065
    [No Abstract]   [Full Text] [Related]  

  • 4. MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Sadeghi N; Li HC
    Ann Hematol; 2018 Apr; 97(4):723-724. PubMed ID: 29285581
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hairy cell leukemia].
    Dietrich S; Zenz T
    Dtsch Med Wochenschr; 2015 Jun; 140(12):882-4. PubMed ID: 26069911
    [No Abstract]   [Full Text] [Related]  

  • 6. [Successful treatment of refractory hairy cell leukemia with rituximab].
    Onaka T; Ozumi N; Yonezawa A; Imada K
    Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1987-9. PubMed ID: 19764485
    [No Abstract]   [Full Text] [Related]  

  • 7. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
    Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
    Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting MEK in vemurafenib-resistant hairy cell leukemia.
    Caeser R; Collord G; Yao WQ; Chen Z; Vassiliou GS; Beer PA; Du MQ; Scott MA; Follows GA; Hodson DJ
    Leukemia; 2019 Feb; 33(2):541-545. PubMed ID: 30341394
    [No Abstract]   [Full Text] [Related]  

  • 9. Nanomedicine against multidrug resistance in cancer treatment.
    Gao J; Feng SS; Guo Y
    Nanomedicine (Lond); 2012 Apr; 7(4):465-8. PubMed ID: 22471716
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cyclic hydroxamic acids as chemosensitizers in cytostatic therapy].
    Konovalova NP; Vystoron IV; Sashenkova TE; Klimanova EN; Mishchenko DV; Allaiarova UIu; Goncharova SA; Raevskaia TA; Iakushchenko TN; Cherniak AV
    Vopr Onkol; 2013; 59(5):620-2. PubMed ID: 24260891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reversal of multidrug resistance: an update.
    Kellen JA
    J Exp Ther Oncol; 2003; 3(1):5-13. PubMed ID: 12724854
    [No Abstract]   [Full Text] [Related]  

  • 12. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hairy cell leukemia with concurrent cryptococcus infection.
    Audeh YM; Gruszecki AC; Cherrington A; Reddy VV
    Am J Hematol; 2003 Mar; 72(3):223-4. PubMed ID: 12605398
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab as frontline monotherapy in untreated hairy cell leukemia patients.
    Akinosoglou K; Melachrinou M; Makatsoris T; Sakellakis M; Papakonstantinou C; Gogos CA; Solomou EE
    Ann Hematol; 2015 Jun; 94(6):1069-70. PubMed ID: 25672650
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
    Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
    Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of hairy-cell leukemia.
    Saven A
    N Engl J Med; 2001 Nov; 345(20):1500-1. PubMed ID: 11794207
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of rituximab in hairy cell leukemia treatment.
    Zinzani PL; Ascani S; Piccaluga PP; Bendandi M; Pileri S; Tura S
    J Clin Oncol; 2000 Nov; 18(22):3875-7. PubMed ID: 11078503
    [No Abstract]   [Full Text] [Related]  

  • 18. Multidrug resistance reversal agents.
    Robert J; Jarry C
    J Med Chem; 2003 Nov; 46(23):4805-17. PubMed ID: 14584929
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of hairy cell leukemia in a patient with antiphospholipid syndrome.
    Diz-Kucukkaya R; Dincol G; Kamali S; Kural F; Inanc M
    Lupus; 2007; 16(4):286-8. PubMed ID: 17439936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab.
    Sasaki M; Sugimoto K; Mori T; Karasawa K; Oshimi K
    Acta Haematol; 2008; 119(1):48-53. PubMed ID: 18259114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.